GSK Reports Over $40 Billion Annual Revenue with Tumor Drug Sales Doubling in 2024
GSK
Pharmaceutical R&D Manufacturer
On February 5, GlaxoSmithKline (GSK) released its 2024 financial report,ChinaRevenue of £31.376 billion (£40.127 billion), an increase of 7% year-on-year (at constant exchange rates, the same below).R&D investment of 6.401 billion pounds($8.186 billion), an increase of 5% year-on-year.
GSK's business is mainly divided intoSpecialty Medicines, Vaccines, and General MedicinesThe three segments contributed revenue of £11.81 billion (£15.105 billion, +19%), £9.138 billion (£11.685 billion, -4%), and £10.428 billion (£13.340 billion, +6%) respectively in 2024.
Oncology Drug Sales Double
GSK's oncology segment growth was mainly driven by the launch of Ojjaara/Omjjara (Momelotinib, launched in September 2023) for patients with myelofibrosis-related anemia, and the expansion of new indications and increased market penetration of PD-1 inhibitor Jemperli (Dostarlimab, launched in April 2021). The sales of the two products in 2024 were £353 million and £467 million, respectively.Increase exceeding 100%。
In the respiratory/immunology field, Nucala (mepolizumab) and Benlysta (belimumab) contributed £1.784 billion (+12%) and £1.490 billion (+14%) in sales respectively to GSK.
In the HIV field, GSK holds long-acting products with remarkable market performance and continuously growing sales. Cabenuva (Cabotegravir + Rilpivirine), Apretude (Cabotegravir), and Dovato (Dolutegravir + Lamivudine) generated revenues of £1.013 billion (+47%), £279 million (+93%), and £2.239 billion (+27%), respectively.
In terms of vaccines, GSK product salesFalling into a slump, incomeOverall 4% decline, with only the meningitis vaccine achieving double-digit growth, while the highly anticipated RSV vaccine...Arexvy Sales Halved.
Arexvy inFirst approved by the FDA in May 2023, and subsequently launched in the EU and Japan. As the world's first RSV vaccine,Arexvy Achieved $1.543 Billion in Sales in Its First Year on the Market. However, in 2024, Due to Decreased Demand, Global Sales of the Product Fell by 51%, Generating Revenue of Only £590 Million.
Shingrix is a recombinant zoster vaccine, 2024Annual revenue of 3.364 billion pounds (+1%) secures GSK's position as the leading global vaccine manufacturer. GSK disclosed in its financial report,Shingrix Sales in China Decline.
Fortunately, the strong growth of meningitis vaccines Meningitis (including Bexsero and Menveo) has injected new momentum into GSK's vaccine sector, achieving sales of £1.437 billion in 2024, a year-on-year increase of 18%.
RecentlyFor two years, to offset the impact of a sluggish pharmaceuticals business, GSK has been actively pursuing mergers and acquisitions. Data from the Insight database shows that GSKIn 2024, a total of 14 pharmaceutical deals were reached., including the acquisition of Aiolos Bio and Elsie Biotechnologies, the introduction of Yingen Bio's novel ADC product DB-1324, and multiple mRNA vaccines from CureVac.
At the beginning of this year, GSK made the first BD deal of the New Year by acquiring IDRx for a $1 billion upfront payment to obtain a gastrointestinal cancer candidate drug.
In 2025, GSK is expected to gain regulatory approval for five new products, including:
Belantamab mafodotin (Blenrep,BCMA ADC), and has been submitted in 2024 in countries and regions such as Europe, Japan, China, and the United States.Indication for Multiple MyelomaMarketing Application; Demokimab (Depemokimab,Long-acting IL-5 Antibody), January 2025, submission for marketing approval in China; Mepolizumab (Nucala,IL-5 Antibody), submitted a new indication marketing application for eosinophilic chronic obstructive pulmonary disease in the United States in December 2024; Gepotidacin is the first new oral antibiotic for the treatment of urinary tract infections in over 20 years, and was submitted for marketing approval in the United States in October 2024. MenABCWY (Quintivalent Meningococcal Vaccine), submitted for market approval in the U.S. in April 2024, used for the prevention of meningococcal disease.
GSK ExpectationsRevenue growth of 3~5% in 2025, income exceeding 40 billion pounds in 2031。
Cover Source:Corporate Logo
Disclaimer:This article is for information sharing only,不代表 Insight 立场和观点, and does not recommend or introduce any treatment options. If needed, please consult and contact正规医疗机构.
Editor: Crescent
PR Article Coordination: WeChat insightxb
SubmissionWeChat: insightxb; Email: insight@dxy.cn
Diversified functions, traceable data……
Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock！
